
MOLN Stock Forecast & Price Target
MOLN Analyst Ratings
Bulls say
Molecular Partners is a clinical-stage biopharmaceutical company with a robust pipeline of clinical and preclinical programs in the field of oncology, specifically targeting DLL3. With radiotheranostics being viewed as a field with strong future potential and an estimated market size of $1.7 billion to $6.0 billion, Molecular Partners has the potential to capture a significant portion of this market and generate substantial revenue. The recent FDA approval of a DLL3-targeted therapy from Amgen further validates the potential success of therapies targeting DLL3 and Molecular Partners' approach with MP0712. Risks include negative clinical results, delays in advancing pipeline candidates, and competitive risks.
Bears say
Molecular Partners is facing financial challenges as they plan a follow-on offering in October 2024, indicating a potential future cash flow deficit as they await clinical trial successes and life-saving regulatory approvals for their flagship products. The biopharma industry is strongly regulated and subject to government intervention as seen in the company's previous experience, posing risks to their future operations. Additionally, the company may struggle to achieve profitability and market share against well-established competitors and may face challenges in effectively penetrating target markets due to limited commercial infrastructure.
This aggregate rating is based on analysts' research of Molecular Partners AG and is not a guaranteed prediction by Public.com or investment advice.
MOLN Analyst Forecast & Price Prediction
Start investing in MOLN
Order type
Buy in
Order amount
Est. shares
0 shares